DFURegen Platform delivers effective, customized regenerative therapy for treating diabetic foot ulcer by using autologous solution with our 4D disruptive technology.
As a leading innovative company, ROKIT has brought a new paradigm in regenerative therapy enhancing both efficacy and safety proven through global clinical studies.

Better for Humanity
DFU Regeneration Platform
Characteristic
AUTOLOGOUS ADIPOSE TISSUE
NO IMMUNE REJECTION
4D BIOPRINTING TECHNOLOGY
MIMIC NATIVE STRUCTURE
OF HUMAN BODY
OF HUMAN BODY
ONE-TIME TREATMENT
NO HOSPITALIZATION
FAST WOUND CLOSURE
PREVENT INFECTION
PREVENT INFECTION
NO AMPUTATION
Clinical Result
Proven Therapeutic Efficacy & Safety for DFU
DFURegen conducted global clinical studies and demonstrated that a single treatment of AMHAT stimulates wound healing by accelerating re-epithelialization of the chronic wound site. AMHAT is derived from patient’s own (autologous) adipose tissue composed of hundreds of proteins, growth factors and cytokines that are essential for wound-healing. In addition to autologous solution, disruptive 4D bioprinting technology delivers customized therapy for healing of refractory diabetic foot ulcers. This is a potent alternative approach for the diabetic patients suffering from non-healing chronic wounds, providing an opportunity for patients to live a better life.

Wound Closure
Video
Diabetic Foot Ulcer Regeneration
CONTACT INQUIRY
We are always here to help you